<ul>
<li><em>BioNTech 已完成收购 CureVac 的交换要约</em></li>
<li><em>此次收购补充了 BioNTech 在 mRNA 设计、递送配方和 mRNA 生产方面的能力和专有技术</em></li>
<li><em>总计约 86.75% 的 CureVac 股份被提交；BioNTech 预计将在 2026 年 1 月完成对剩余 CureVac 股份的强制收购，作为之前宣布的要约后重组的一部分</em></li>
<li><em>CureVac 将继续在其现有的组织流程下运营，而 BioNTech 将完成所需的战略、运营和科学分析，以定义未来的组织和投资组合设置</em></li>
</ul>
<p><strong>德国美因茨，2025 年 12 月 18 日</strong>– BioNTech SE（纳斯达克：BNTX，“BioNTech” 或 “公司”）今天宣布已完成对 CureVac N.V.（纳斯达克：CVAC，“CureVac”）的收购，并且对所有未偿还 CureVac 股份的交换要约的后续要约期（“后续要约期”）于今天凌晨 12:01（东部时间）到期。通过成功收购，BioNTech 打算进一步补充其在 mRNA 设计、递送配方和 mRNA 生产方面的能力和专有技术。此次收购建立在 BioNTech 在全球 mRNA 行业的良好业绩和既定地位之上，并支持公司在肿瘤学战略的执行，该战略专注于两个全肿瘤项目：基于 mRNA 的癌症免疫疗法候选药物，以及与百时美施贵宝公司（纽约证券交易所：BMY，“BMS”）共同开发的双特异性抗体候选药物 pumitamig（BNT327/BMS986545），该药物靶向 PD-L1 和 VEGF-A。</p>
<p>“我想感谢所有帮助使这笔交易成功的人。这深化了我们的 mRNA 技术平台，并提供了扩展我们开发 mRNA 作为新治疗药物类别的潜力，”<strong>BioNTech 首席执行官兼联合创始人 Ugurs Sahin 教授，医学博士</strong> 表示。“凭借一款已获批准的 mRNA 产品和多个涵盖不同作用机制的后期项目，我们正在推进新一代药物，旨在为患者提供实质性益处。”</p>
<p>“通过这次收购，德国早期 mRNA 公司的开创性努力得以结合——愿景与技术的协同。两者都源于德国并非偶然，背后有如 ATHOS KG 和 dievini Hopp BioTech holding 等具有企业精神的长期导向家族办公室的支持，”<strong>BioNTech 监事会主席 Helmut Jeggle</strong> 表示。“这笔交易具有显著潜力，有助于推动国家的创新议程，以塑造而不仅仅是跟随下一波具有全球影响力的创新。”</p>
<p>收购完成后，Ugurs Sahin 教授，医学博士，Sierk Poetting 博士和 Ramón Zapata-Gomez 将组成 CureVac SE 的管理委员会，CureVac SE 管理委员会的前成员自愿辞去职务。CureVac 将保持其现有的组织流程，以确保业务的无缝连续性，而 BioNTech 将完成所需的战略、运营和科学分析，以定义未来的组织和投资组合设置。</p>
<p>BioNTech 收到交换要约的交换代理 Computershare Trust Company, N.A.的通知，截至后续要约期的到期时间，共有 195,341,219 股 CureVac 股份有效提交，合计约占 CureVac 已发行和流通股份的 86.75%。公司预计将在 2026 年 1 月完成对剩余 CureVac 股份的强制收购，作为之前宣布的要约后重组的一部分。CureVac 股份将在要约后重组后不再可交易。</p>
<p>有关要约的更多信息，包括要约后重组，已在 BioNTech 于 2025 年 11 月 26 日和 2025 年 12 月 3 日发布的新闻稿中详细说明。</p>
<p><strong>关于 BioNTech</strong></p>
<p>生物制药新技术（BioNTech）是一家全球领先的下一代免疫疗法公司，开创了针对癌症和其他严重疾病的新型研究疗法。BioNTech 利用广泛的计算发现和治疗方式，旨在快速开发新型生物制药。其多样化的肿瘤产品候选组合旨在解决癌症的全谱系，包括 mRNA 癌症免疫疗法、下一代免疫调节剂和靶向疗法，如抗体药物偶联物（ADCs）和创新的嵌合抗原受体（CAR）T 细胞疗法。基于其在 mRNA 开发和内部制造能力方面的深厚专业知识，BioNTech 及其合作伙伴正在研究和开发多种针对一系列传染病的 mRNA 疫苗候选药物，同时推进其多样化的肿瘤管线。BioNTech 已与多家全球和专业制药合作伙伴建立了广泛的关系，包括百时美施贵宝、Duality Biologics、复星医药、基因泰克（罗氏集团成员）、Genmab、MediLink、OncoC4、辉瑞和再生元。</p>
<p>欲了解更多信息，请访问 www.BioNTech.com。</p>
<p><strong>关于前瞻性声明的警示声明</strong></p>
<p>本文件包含 “前瞻性声明”。前瞻性声明通常可以通过诸如 “潜在”、“可以”、“将”、“计划”、“可能”、“能够”、“会”、“期望”、“期待”、“调查性”、“管道”、“收购”、“开发”、“包括”、“承诺” 或类似术语来识别。这些前瞻性声明包括但不限于与 2025 年 6 月 12 日 BioNTech 与 CureVac 之间的购买协议（“购买协议”）相关的要约及其他交易的声明，交易所期望实现的利益，交易后 BioNTech 的潜力和能力，以及交易对 BioNTech 和 CureVac 的潜在影响。这些风险和不确定性中的许多超出了 BioNTech 或 CureVac 的控制范围。投资者被提醒，任何此类前瞻性声明均基于 BioNTech 对未来事件的当前信念和期望，并不保证未来的表现，并涉及风险和不确定性。如果基本假设被证明不准确或风险或不确定性实现，实际结果可能与前瞻性声明中所述的结果有重大差异。您不应对这些声明过度依赖。</p>
<p>风险和不确定性包括但不限于，购买协议所涉及交易的干扰影响，以及交易对 BioNTech 业务的影响，包括与员工、商业伙伴或政府实体的关系；与交易相关的任何法律程序的结果；由于购买协议所涉及的交易或其他原因，管理层对持续业务运营和机会的注意力分散；一般行业状况和竞争；一般政治、经济和商业状况，包括利率、通货膨胀、关税和汇率波动，以及持续的俄罗斯 - 乌克兰和中东冲突；美国、欧洲及欧洲以外国家和地区的监管发展和变化的影响，包括税务事项；美国、欧洲及其他地区制药行业监管和医疗保健立法的影响；医生和患者的特定处方偏好；来自其他产品的竞争；新产品开发中固有的挑战和不确定性；获得或维持专有知识产权保护的能力；安全、质量、数据完整性或制造问题；以及潜在或实际的数据安全和数据隐私泄露。</p>
<p>BioNTech 不承担任何义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。可能导致结果与前瞻性声明中描述的结果有重大差异的其他因素可以在 BioNTech 截至 2024 年 12 月 31 日的 20-F 表格年度报告中找到，该报告已通过与 SEC 的后续提交进行修订，相关文件可在 SEC 网站 www.sec.gov 上获取。</p>
<p><strong>联系方式</strong></p>
<p><strong>投资者关系</strong></p>
<p>道格拉斯·马菲博士</p>
<p>Investors@BioNTech.de</p>
<p><strong>媒体关系</strong></p>
<p>贾斯米娜·阿拉托维奇</p>
<p>Media@BioNTech.de</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVFU0TlNNME1ESXlPRFV5TnpJak1qQXdNRGs0TlE9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVFU0TlNNME1ESXlPRFV5TnpJak1qQXdNRGs0TlE9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png"/></p>

BNTX

CVAC

<p>BioNTech 已完成对 CureVac 的收购，增强了其 mRNA 能力。约 86.75% 的 CureVac 股份已被提交，剩余股份预计将在 2026 年 1 月前收购。CureVac 将继续运营，同时 BioNTech 将整合战略和科学分析。这项收购巩固了 BioNTech 在 mRNA 领域的地位，并支持其肿瘤学战略。CureVac 的管理委员会将在收购后重新组成</p>

<ul>
<li><em>BioNTech has completed its exchange offer to acquire CureVac</em></li>
<li><em>Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing</em></li>
<li><em>In total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization</em></li>
<li><em>CureVac will continue to operate under its existing organizational processes, while BioNTech will conclude the strategic, operational, and scientific analyses required to define the future organizational and portfolio setup</em></li>
</ul>
<div class="lb-trans"><ul>
<li><em>BioNTech 已完成收购 CureVac 的交换要约</em></li>
<li><em>此次收购补充了 BioNTech 在 mRNA 设计、递送配方和 mRNA 生产方面的能力和专有技术</em></li>
<li><em>总计约 86.75% 的 CureVac 股份被提交；BioNTech 预计将在 2026 年 1 月完成对剩余 CureVac 股份的强制收购，作为之前宣布的要约后重组的一部分</em></li>
<li><em>CureVac 将继续在其现有的组织流程下运营，而 BioNTech 将完成所需的战略、运营和科学分析，以定义未来的组织和投资组合设置</em></li>
</ul>
</div><p><strong>MAINZ, Germany, December 18, 2025</strong>– BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful acquisition, BioNTech intends to further complement its capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. The acquisition builds on BioNTech’s proven track record and established position in the global mRNA industry and supports the execution of the Company’s oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 and VEGF-A, which is being jointly developed with Bristol Myers Squibb Company (NYSE: BMY, “BMS”).</p>
<div class="lb-trans"><p><strong>德国美因茨，2025 年 12 月 18 日</strong>– BioNTech SE（纳斯达克：BNTX，“BioNTech” 或 “公司”）今天宣布已完成对 CureVac N.V.（纳斯达克：CVAC，“CureVac”）的收购，并且对所有未偿还 CureVac 股份的交换要约的后续要约期（“后续要约期”）于今天凌晨 12:01（东部时间）到期。通过成功收购，BioNTech 打算进一步补充其在 mRNA 设计、递送配方和 mRNA 生产方面的能力和专有技术。此次收购建立在 BioNTech 在全球 mRNA 行业的良好业绩和既定地位之上，并支持公司在肿瘤学战略的执行，该战略专注于两个全肿瘤项目：基于 mRNA 的癌症免疫疗法候选药物，以及与百时美施贵宝公司（纽约证券交易所：BMY，“BMS”）共同开发的双特异性抗体候选药物 pumitamig（BNT327/BMS986545），该药物靶向 PD-L1 和 VEGF-A。</p>
</div><p>“I want to thank everyone who helped make this transaction a success. It deepens our mRNA technology platform and offers potential to expand the ways we can develop mRNA as a new therapeutic drug class,” said <strong>Prof. Ugur Sahin, M.D.,</strong> <strong>CEO and Co-Founder of BioNTech</strong>. “With an approved mRNA product and multiple late-stage programs spanning distinct mechanisms of action, we are advancing a new generation of medicines aimed at delivering meaningful benefits for patients.”</p>
<div class="lb-trans"><p>“我想感谢所有帮助使这笔交易成功的人。这深化了我们的 mRNA 技术平台，并提供了扩展我们开发 mRNA 作为新治疗药物类别的潜力，”<strong>BioNTech 首席执行官兼联合创始人 Ugurs Sahin 教授，医学博士</strong> 表示。“凭借一款已获批准的 mRNA 产品和多个涵盖不同作用机制的后期项目，我们正在推进新一代药物，旨在为患者提供实质性益处。”</p>
</div><p>“With this acquisition, the pioneering efforts of two of Germany’s early mRNA firms are being brought together – a synergy of vision and technology. It is no coincidence that both originated in Germany, backed by dedicated long-term oriented family offices with an entrepreneurial spirit such as ATHOS KG and the dievini Hopp BioTech holding,” said <strong>Helmut Jeggle, Chairman of the BioNTech Supervisory Board</strong>. “This transaction has significant potential to contribute to the country’s innovation agenda to shape, not just follow, the next wave of innovation with global impact.”</p>
<div class="lb-trans"><p>“通过这次收购，德国早期 mRNA 公司的开创性努力得以结合——愿景与技术的协同。两者都源于德国并非偶然，背后有如 ATHOS KG 和 dievini Hopp BioTech holding 等具有企业精神的长期导向家族办公室的支持，”<strong>BioNTech 监事会主席 Helmut Jeggle</strong> 表示。“这笔交易具有显著潜力，有助于推动国家的创新议程，以塑造而不仅仅是跟随下一波具有全球影响力的创新。”</p>
</div><p>Following the closing of the acquisition, Prof. Ugur Sahin, M.D., Sierk Poetting, Ph.D., and Ramón Zapata-Gomez will constitute the Management Board of CureVac SE as the former members of the CureVac SE Management Board voluntarily resigned from their positions. CureVac will maintain its existing organizational processes to ensure a seamless continuity of its business, while BioNTech will conclude the strategic, operational and scientific analyses required to define the future organizational and portfolio setup.</p>
<div class="lb-trans"><p>收购完成后，Ugurs Sahin 教授，医学博士，Sierk Poetting 博士和 Ramón Zapata-Gomez 将组成 CureVac SE 的管理委员会，CureVac SE 管理委员会的前成员自愿辞去职务。CureVac 将保持其现有的组织流程，以确保业务的无缝连续性，而 BioNTech 将完成所需的战略、运营和科学分析，以定义未来的组织和投资组合设置。</p>
</div><p>BioNTech was informed by Computershare Trust Company, N.A., the exchange agent for the Offer, that, as of the expiration time of the Subsequent Offering Period, a total of 195,341,219 CureVac shares, collectively representing approximately 86.75% of CureVac’s issued and outstanding shares, were validly tendered in the Offer. The Company expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization. CureVac shares will no longer be available for trading following the post-offer reorganization.</p>
<div class="lb-trans"><p>BioNTech 收到交换要约的交换代理 Computershare Trust Company, N.A.的通知，截至后续要约期的到期时间，共有 195,341,219 股 CureVac 股份有效提交，合计约占 CureVac 已发行和流通股份的 86.75%。公司预计将在 2026 年 1 月完成对剩余 CureVac 股份的强制收购，作为之前宣布的要约后重组的一部分。CureVac 股份将在要约后重组后不再可交易。</p>
</div><p>Further information on the Offer, including the post-offer reorganization, was previously laid out in BioNTech press releases issued on November 26, 2025 and December 3, 2025.</p>
<div class="lb-trans"><p>有关要约的更多信息，包括要约后重组，已在 BioNTech 于 2025 年 11 月 26 日和 2025 年 12 月 3 日发布的新闻稿中详细说明。</p>
</div><p><strong>About BioNTech</strong></p>
<div class="lb-trans"><p><strong>关于 BioNTech</strong></p>
</div><p>Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.</p>
<div class="lb-trans"><p>生物制药新技术（BioNTech）是一家全球领先的下一代免疫疗法公司，开创了针对癌症和其他严重疾病的新型研究疗法。BioNTech 利用广泛的计算发现和治疗方式，旨在快速开发新型生物制药。其多样化的肿瘤产品候选组合旨在解决癌症的全谱系，包括 mRNA 癌症免疫疗法、下一代免疫调节剂和靶向疗法，如抗体药物偶联物（ADCs）和创新的嵌合抗原受体（CAR）T 细胞疗法。基于其在 mRNA 开发和内部制造能力方面的深厚专业知识，BioNTech 及其合作伙伴正在研究和开发多种针对一系列传染病的 mRNA 疫苗候选药物，同时推进其多样化的肿瘤管线。BioNTech 已与多家全球和专业制药合作伙伴建立了广泛的关系，包括百时美施贵宝、Duality Biologics、复星医药、基因泰克（罗氏集团成员）、Genmab、MediLink、OncoC4、辉瑞和再生元。</p>
</div><p>For more information, please visit www.BioNTech.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.BioNTech.com。</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示声明</strong></p>
</div><p>This document includes “forward-looking statements.” Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “look forward,” “investigational,” “pipeline,” “to acquire,” “development,” “to include,” “commitment,” or similar terms. Such forward-looking statements include, but are not limited to, statements relating to the Offer and other transactions contemplated by the purchase agreement, dated June 12, 2025, by and between BioNTech and CureVac (the “Purchase Agreement”), the benefits sought to be achieved in the transactions, the potential and capacity of BioNTech following the transaction, and the potential effects of the transactions on BioNTech and CureVac. Many of these risks and uncertainties are beyond the control of BioNTech or CureVac. Investors are cautioned that any such forward-looking statements are based on BioNTech’s current beliefs and expectations regarding future events and are not guarantees of future performance and involve risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.</p>
<div class="lb-trans"><p>本文件包含 “前瞻性声明”。前瞻性声明通常可以通过诸如 “潜在”、“可以”、“将”、“计划”、“可能”、“能够”、“会”、“期望”、“期待”、“调查性”、“管道”、“收购”、“开发”、“包括”、“承诺” 或类似术语来识别。这些前瞻性声明包括但不限于与 2025 年 6 月 12 日 BioNTech 与 CureVac 之间的购买协议（“购买协议”）相关的要约及其他交易的声明，交易所期望实现的利益，交易后 BioNTech 的潜力和能力，以及交易对 BioNTech 和 CureVac 的潜在影响。这些风险和不确定性中的许多超出了 BioNTech 或 CureVac 的控制范围。投资者被提醒，任何此类前瞻性声明均基于 BioNTech 对未来事件的当前信念和期望，并不保证未来的表现，并涉及风险和不确定性。如果基本假设被证明不准确或风险或不确定性实现，实际结果可能与前瞻性声明中所述的结果有重大差异。您不应对这些声明过度依赖。</p>
</div><p>Risks and uncertainties include, but are not limited to, the effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the transactions on BioNTech’s business, including its relationships with employees, business partners or governmental entities; the outcome of any legal proceedings relating to the transactions; a diversion of management’s attention from ongoing business operations and opportunities as a result of the transactions contemplated by the Purchase Agreement or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and the ongoing Russia-Ukraine and Middle East conflicts; the impact of regulatory developments and changes in the United States, Europe and countries and regions outside of Europe, including with respect to tax matters; the impact of pharmaceutical industry regulation and health care legislation in the United States, Europe and elsewhere; the particular prescribing preferences of physicians and patients; competition from other products; challenges and uncertainties inherent in new product development; ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; and potential or actual data security and data privacy breaches.</p>
<div class="lb-trans"><p>风险和不确定性包括但不限于，购买协议所涉及交易的干扰影响，以及交易对 BioNTech 业务的影响，包括与员工、商业伙伴或政府实体的关系；与交易相关的任何法律程序的结果；由于购买协议所涉及的交易或其他原因，管理层对持续业务运营和机会的注意力分散；一般行业状况和竞争；一般政治、经济和商业状况，包括利率、通货膨胀、关税和汇率波动，以及持续的俄罗斯 - 乌克兰和中东冲突；美国、欧洲及欧洲以外国家和地区的监管发展和变化的影响，包括税务事项；美国、欧洲及其他地区制药行业监管和医疗保健立法的影响；医生和患者的特定处方偏好；来自其他产品的竞争；新产品开发中固有的挑战和不确定性；获得或维持专有知识产权保护的能力；安全、质量、数据完整性或制造问题；以及潜在或实际的数据安全和数据隐私泄露。</p>
</div><p>BioNTech does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in BioNTech’s Annual Report on Form 20-F for the year ended December 31, 2024, as amended by any subsequent filings made with the SEC, available on the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>BioNTech 不承担任何义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。可能导致结果与前瞻性声明中描述的结果有重大差异的其他因素可以在 BioNTech 截至 2024 年 12 月 31 日的 20-F 表格年度报告中找到，该报告已通过与 SEC 的后续提交进行修订，相关文件可在 SEC 网站 www.sec.gov 上获取。</p>
</div><p><strong>CONTACTS</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>Douglas Maffei, Ph.D.</p>
<div class="lb-trans"><p>道格拉斯·马菲博士</p>
</div><p>Investors@BioNTech.de</p>
<div class="lb-trans"><p>Investors@BioNTech.de</p>
</div><p><strong>Media Relations</strong></p>
<div class="lb-trans"><p><strong>媒体关系</strong></p>
</div><p>Jasmina Alatovic</p>
<div class="lb-trans"><p>贾斯米娜·阿拉托维奇</p>
</div><p>Media@BioNTech.de</p>
<div class="lb-trans"><p>Media@BioNTech.de</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVFU0TlNNME1ESXlPRFV5TnpJak1qQXdNRGs0TlE9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0NTU4NSM0MDIyODUyNzIjMjAwMDk4NQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png" alt="" original-src="https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png"/></p>

BioNTech 完成了对 CureVac N.V.的收购，包括后续的要约期，以巩固其在 mRNA 领域的独特地位 | BNTX 股票新闻